Fong MW, Lo B, Ho J, Toy C, Fong IW; Conference on Retroviruses and Opportunistic Infections.
Program Abstr 4th Conf Retrovir Oppor Infect Conf Retrovir Oppor Infect 4th 1997 Wash DC. 1997 Jan 22-26; 4th: 195 (abstract no. 709).
St. Michael's Hospital, Toronto, ON, Canada.
Epstein-Barr Virus (EBV) is associated with 100% of non-Hodgkin's lymphoma (NHL) of the brain and 40%-66% of systemic NHL in HIV-infected patients (pts.). Acyclovir (and similar drugs) has antiviral effect against EBV and chronic usage may prevent NHL if there is a causal relationship. 29 pts. with AIDS-related NHL were identified and 58 matched controls were analyzed for acyclovir, ganciclovir and foscarnet usage. Controls were matched to pts. by age plus or minus 5 yrs, sex, underlying risk factor, duration of AIDS or antiretroviral drugs. The number of pts. on continuous high-dose acyclovir (greater than or equal to 800 mg/ day) for greater than or equal to 1 year was analysed. Chronic ganciclovir or foscarnet greater than or equal to 1 year was used in one NHL case and one control. See table below for acyclovir usage: (Table: see text) Prolonged high dose acyclovir may offer some protection against NHL in advanced HIV disease. Further studies are in progress to confirm these results.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Acyclovir
- Antiviral Agents
- Case-Control Studies
- Foscarnet
- Ganciclovir
- HIV Infections
- HIV Seropositivity
- Herpesvirus 4, Human
- Humans
- Lymphoma, AIDS-Related
- Lymphoma, Non-Hodgkin
- Pharmaceutical Preparations
- Risk Factors
Other ID:
UI: 102225259
From Meeting Abstracts